Galvanize Therapeutics raises $100 million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease
Sofinnova Partners leads premier investor syndicate backing Galvanize’s breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD. REDWOOD CITY, Calif., Sept. 3, 2025 /PRNewswire/ — Galvanize…